Identification

Name
Zimelidine
Accession Number
DB04832
Type
Small Molecule
Groups
Withdrawn
Description

Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.

Structure
Thumb
Synonyms
  • (Z)-3-(4'-Bromophenyl)-3-(3''-pyridyl)dimethylallylamine
  • (Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine
  • (z)-zimelidine
  • Cis-zimelidine
  • Zimeldine
Categories
UNII
3J928617DW
CAS number
56775-88-3
Weight
Average: 317.224
Monoisotopic: 316.057511201
Chemical Formula
C16H17BrN2
InChI Key
OYPPVKRFBIWMSX-SXGWCWSVSA-N
InChI
InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
IUPAC Name
[3-(4-bromophenyl)-3-(pyridin-3-yl)prop-2-en-1-yl]dimethylamine
SMILES
CN(C)CC=C(C1=CC=C(Br)C=C1)C1=CN=CC=C1

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics

Zimelidine was the first marketed selective serotonin reuptake inhibitor (SSRI) antidepressant. It is a pyridylallylamine, structurally different from other antidepressants.

Mechanism of action

The antidepressant actions of zimelidine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Zimelidine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

TargetActionsOrganism
USodium-dependent serotonin transporterNot AvailableHuman
UAmine oxidase [flavin-containing] B
inhibitor
Human
UAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

8.4 +/- 2.0 hours for the parent compound and 19.4 +/- 3.6 hours for norzimelidine.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Zimelidine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Zimelidine.Experimental
AcarboseZimelidine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolZimelidine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zimelidine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zimelidine.Approved
Acetylsalicylic acidZimelidine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Zimelidine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Zimelidine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zimelidine.Approved, Investigational
AlaproclateZimelidine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideZimelidine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zimelidine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Zimelidine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Zimelidine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Zimelidine.Investigational
AlogliptinZimelidine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Zimelidine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Zimelidine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zimelidine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Zimelidine.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Zimelidine.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zimelidine.Approved, Illicit
AmoxapineZimelidine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Zimelidine.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Zimelidine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Zimelidine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Zimelidine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Zimelidine.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zimelidine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Zimelidine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Zimelidine.Experimental
BendroflumethiazideZimelidine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Zimelidine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Zimelidine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zimelidine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zimelidine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Zimelidine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.Approved
BezitramideBezitramide may increase the serotonergic activities of Zimelidine.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Zimelidine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Zimelidine.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Zimelidine.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Zimelidine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Zimelidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Zimelidine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Zimelidine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zimelidine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Zimelidine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Zimelidine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zimelidine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Zimelidine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Zimelidine.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Zimelidine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zimelidine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Zimelidine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Zimelidine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Zimelidine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Zimelidine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Zimelidine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Zimelidine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Zimelidine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Zimelidine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Zimelidine.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Zimelidine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zimelidine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Zimelidine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zimelidine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Zimelidine.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Zimelidine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Zimelidine.Approved, Investigational
CelecoxibZimelidine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Zimelidine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zimelidine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zimelidine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zimelidine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Zimelidine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zimelidine.Approved
ChlorothiazideZimelidine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Zimelidine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Zimelidine.Experimental
ChlorpropamideZimelidine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine.Approved, Investigational, Withdrawn
ChlorthalidoneZimelidine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zimelidine.Approved
CimetidineThe metabolism of Zimelidine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zimelidine.Approved, Vet Approved
CitalopramCitalopram may increase the serotonergic activities of Zimelidine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Zimelidine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Zimelidine.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Zimelidine.Investigational
ClomipramineZimelidine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Zimelidine.Approved, Illicit
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Zimelidine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Zimelidine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zimelidine.Approved, Illicit
ClorindioneZimelidine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Zimelidine.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Zimelidine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zimelidine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Zimelidine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Zimelidine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Zimelidine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.Approved
CyclopenthiazideZimelidine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyproheptadineThe therapeutic efficacy of Zimelidine can be decreased when used in combination with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Zimelidine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zimelidine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zimelidine.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Zimelidine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Zimelidine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zimelidine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zimelidine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zimelidine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Zimelidine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Zimelidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zimelidine.Approved, Vet Approved
DextromethorphanZimelidine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Zimelidine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Zimelidine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Zimelidine.Approved, Investigational
DicoumarolZimelidine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Zimelidine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Zimelidine.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Zimelidine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Zimelidine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Zimelidine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zimelidine.Approved
DiphenadioneZimelidine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zimelidine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Zimelidine.Approved, Illicit
DisopyramideZimelidine may increase the hypoglycemic activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Zimelidine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Zimelidine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Zimelidine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Zimelidine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Zimelidine.Approved, Investigational
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Zimelidine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Zimelidine.Investigational
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Zimelidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Zimelidine.Experimental, Illicit
DulaglutideZimelidine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Zimelidine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Zimelidine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Zimelidine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Zimelidine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zimelidine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Zimelidine.Investigational
EmpagliflozinZimelidine may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zimelidine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Zimelidine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Zimelidine.Experimental
EscitalopramEscitalopram may increase the serotonergic activities of Zimelidine.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Zimelidine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zimelidine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zimelidine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Zimelidine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zimelidine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zimelidine.Approved
Ethyl biscoumacetateZimelidine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Zimelidine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zimelidine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Zimelidine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Zimelidine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Zimelidine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Zimelidine.Approved
EtodolacZimelidine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Zimelidine.Withdrawn
EtoricoxibZimelidine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Zimelidine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Zimelidine.Approved
ExenatideZimelidine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Zimelidine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Zimelidine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zimelidine.Approved, Illicit, Withdrawn
FenfluramineZimelidine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Zimelidine.Approved, Illicit, Investigational, Vet Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zimelidine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Zimelidine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine.Approved, Illicit
FluindioneZimelidine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Zimelidine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zimelidine.Approved, Illicit
FluoxetineFluoxetine may increase the serotonergic activities of Zimelidine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zimelidine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zimelidine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zimelidine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Zimelidine.Approved
FluvoxamineFluvoxamine may increase the serotonergic activities of Zimelidine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Zimelidine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zimelidine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Zimelidine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zimelidine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Zimelidine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Zimelidine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zimelidine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Zimelidine.Investigational
GliclazideZimelidine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideZimelidine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideZimelidine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Zimelidine.Approved, Illicit
GlyburideZimelidine may increase the hypoglycemic activities of Glyburide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zimelidine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zimelidine.Approved, Illicit, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Zimelidine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Zimelidine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zimelidine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Zimelidine.Experimental
HydrochlorothiazideZimelidine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Zimelidine.Approved, Illicit
HydroflumethiazideZimelidine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Zimelidine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Zimelidine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zimelidine.Approved
IndalpineIndalpine may increase the serotonergic activities of Zimelidine.Investigational, Withdrawn
IndapamideZimelidine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Zimelidine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Zimelidine.Investigational
Insulin AspartZimelidine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirZimelidine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineZimelidine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineZimelidine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanZimelidine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproZimelidine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Zimelidine.Approved, Investigational
Ioflupane I-123Zimelidine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Zimelidine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Zimelidine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Zimelidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zimelidine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zimelidine.Approved, Vet Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Zimelidine.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Zimelidine.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Zimelidine.Approved
LandiololThe serum concentration of Landiolol can be increased when it is combined with Zimelidine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Zimelidine.Approved
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Zimelidine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zimelidine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Zimelidine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zimelidine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Zimelidine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Zimelidine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Zimelidine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Zimelidine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Zimelidine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zimelidine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Zimelidine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Zimelidine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Zimelidine.Approved
LiraglutideZimelidine may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Zimelidine.Approved
LofentanilLofentanil may increase the serotonergic activities of Zimelidine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Zimelidine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zimelidine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zimelidine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Zimelidine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zimelidine.Approved
LumiracoxibZimelidine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Zimelidine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine.Approved
MebanazineMebanazine may increase the serotonergic activities of Zimelidine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Zimelidine.Experimental
MecaserminZimelidine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Zimelidine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Zimelidine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Zimelidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Zimelidine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Zimelidine.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Zimelidine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zimelidine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Zimelidine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zimelidine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.Approved
MetforminZimelidine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Zimelidine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Zimelidine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zimelidine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Zimelidine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zimelidine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zimelidine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zimelidine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.Approved
MethyclothiazideZimelidine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zimelidine.Experimental
Methylene blueZimelidine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zimelidine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Zimelidine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zimelidine.Approved, Investigational
MetolazoneZimelidine may increase the hyponatremic activities of Metolazone.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Zimelidine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Zimelidine.Approved
MifepristoneZimelidine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolZimelidine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Zimelidine.Approved
MinaprineMinaprine may increase the serotonergic activities of Zimelidine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zimelidine.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Zimelidine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Zimelidine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Zimelidine.Approved, Investigational, Withdrawn
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Zimelidine.Approved, Investigational
NabumetoneZimelidine may increase the antiplatelet activities of Nabumetone.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Zimelidine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Zimelidine.Approved
NateglinideZimelidine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Zimelidine.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Zimelidine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Zimelidine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Zimelidine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Zimelidine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Zimelidine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zimelidine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Zimelidine.Withdrawn
OlanzapineZimelidine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zimelidine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zimelidine.Approved
OpiumOpium may increase the serotonergic activities of Zimelidine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zimelidine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Zimelidine.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Zimelidine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zimelidine.Approved
OxycodoneOxycodone may increase the serotonergic activities of Zimelidine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Zimelidine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zimelidine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Zimelidine.Approved, Investigational
ParecoxibZimelidine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Zimelidine.Approved
ParoxetineParoxetine may increase the serotonergic activities of Zimelidine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Zimelidine.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Zimelidine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Zimelidine.Experimental
PentamidineZimelidine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Zimelidine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zimelidine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Zimelidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Zimelidine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Zimelidine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zimelidine.Approved
PethidinePethidine may increase the serotonergic activities of Zimelidine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Zimelidine.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Zimelidine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Zimelidine.Experimental
PhenindioneZimelidine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Zimelidine.Withdrawn
PhenoperidinePhenoperidine may increase the serotonergic activities of Zimelidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Zimelidine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Zimelidine.Withdrawn
PhenprocoumonZimelidine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Zimelidine is combined with Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Zimelidine.Approved
PioglitazoneZimelidine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zimelidine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Zimelidine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Zimelidine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Zimelidine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Zimelidine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Zimelidine.Approved
PolythiazideZimelidine may increase the hyponatremic activities of Polythiazide.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Zimelidine.Approved
PramlintideZimelidine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zimelidine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zimelidine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zimelidine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Zimelidine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zimelidine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zimelidine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zimelidine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Zimelidine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zimelidine.Approved, Vet Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Zimelidine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zimelidine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Zimelidine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Zimelidine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Zimelidine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Zimelidine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zimelidine.Approved, Illicit
QuinethazoneZimelidine may increase the hyponatremic activities of Quinethazone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Zimelidine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Zimelidine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Zimelidine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Zimelidine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Zimelidine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine.Approved, Withdrawn
RepaglinideZimelidine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Zimelidine.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Zimelidine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Zimelidine.Investigational
RofecoxibZimelidine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Zimelidine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine.Approved
RosiglitazoneZimelidine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Zimelidine.Withdrawn
SaxagliptinZimelidine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zimelidine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Zimelidine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Zimelidine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Zimelidine.Approved, Investigational, Withdrawn
SertralineSertraline may increase the serotonergic activities of Zimelidine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zimelidine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Zimelidine.Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Zimelidine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Zimelidine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Zimelidine.Approved
SufentanilSufentanil may increase the serotonergic activities of Zimelidine.Approved, Investigational
SulfadiazineZimelidine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleZimelidine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleZimelidine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zimelidine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Zimelidine.Experimental
SunitinibZimelidine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Zimelidine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Zimelidine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Zimelidine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Zimelidine.Investigational
TapentadolTapentadol may increase the serotonergic activities of Zimelidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Zimelidine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zimelidine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Zimelidine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zimelidine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zimelidine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Zimelidine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Zimelidine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zimelidine.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zimelidine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Zimelidine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Zimelidine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zimelidine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zimelidine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zimelidine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Zimelidine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zimelidine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Zimelidine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Zimelidine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Zimelidine.Experimental
TioclomarolZimelidine may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.Approved
TolazamideZimelidine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideZimelidine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zimelidine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Zimelidine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Zimelidine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Zimelidine.Approved, Investigational
TramadolZimelidine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Zimelidine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zimelidine.Approved
TrazodoneZimelidine may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zimelidine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Zimelidine.Vet Approved
TrichlormethiazideZimelidine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Zimelidine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zimelidine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Zimelidine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zimelidine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zimelidine.Approved
ValdecoxibZimelidine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zimelidine.Approved, Investigational
VenlafaxineVenlafaxine may increase the serotonergic activities of Zimelidine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Zimelidine.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Zimelidine.Approved
VilazodoneZimelidine may increase the serotonergic activities of Vilazodone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Zimelidine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Zimelidine.Experimental
VortioxetineZimelidine may increase the serotonergic activities of Vortioxetine.Approved
WarfarinZimelidine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Zimelidine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Zimelidine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zimelidine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Zimelidine.Approved
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Zimelidine.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zimelidine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zimelidine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zimelidine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Zimelidine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zimelidine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Caille G, Kouassi E, de Montigny C: Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40. [PubMed:6228368]
  2. Godbout R, Montplaisir J: The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9(1):46-51. [PubMed:2950994]
External Links
PubChem Compound
41987
PubChem Substance
46504589
ChemSpider
4517305
BindingDB
50020706
ChEBI
135357
ChEMBL
CHEMBL37744
Wikipedia
Zimelidine
ATC Codes
N06AB02 — Zimeldine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0239 mg/mLALOGPS
logP3.39ALOGPS
logP3.51ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity93.94 m3·mol-1ChemAxon
Polarizability30.96 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.972
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7284
P-glycoprotein substrateSubstrate0.6049
P-glycoprotein inhibitor INon-inhibitor0.8435
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.5919
CYP450 2C9 substrateNon-substrate0.8893
CYP450 2D6 substrateNon-substrate0.6656
CYP450 3A4 substrateSubstrate0.5541
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8185
Ames testNon AMES toxic0.8077
CarcinogenicityNon-carcinogens0.807
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.5787 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8348
hERG inhibition (predictor II)Inhibitor0.6614
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Styrenes
Direct Parent
Styrenes
Alternative Parents
Bromobenzenes / Pyridines and derivatives / Aryl bromides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organobromides / Hydrocarbon derivatives
Substituents
Styrene / Bromobenzene / Halobenzene / Aryl bromide / Aryl halide / Pyridine / Heteroaromatic compound / Tertiary aliphatic amine / Tertiary amine / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Egashira T, Takayama F, Yamanaka Y: The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species. Jpn J Pharmacol. 1999 Sep;81(1):115-21. [PubMed:10580379]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Egashira T, Takayama F, Yamanaka Y: Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. Gen Pharmacol. 1996 Jul;27(5):773-8. [PubMed:8842678]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on September 11, 2007 15:01 / Updated on November 09, 2017 03:47